This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
09 February 2009
In the version of this article initially published, we neglected to define our categories for public biotech firms. In the following definitions, the dollar amounts refer to a firm’s market capitalization or ‘cap’: microcap, <$250 million; small cap, $250 million to <$1 billion; mid-cap, $1 billion to <$5 billion; large cap, ≤$5 billion. The definitions have been added to Box 2, Figure 1 legend, in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mitchell, P. Biotech sector ponders potential 'bloodbath'. Nat Biotechnol 27, 3–5 (2009). https://doi.org/10.1038/nbt0109-3
Issue Date:
DOI: https://doi.org/10.1038/nbt0109-3
This article is cited by
-
The Role of Pre-IPO Financial Indicators and Intermediaries in Aftermarket Performance and Survival in the US Biopharmaceutical Market
Journal of Pharmaceutical Innovation (2012)
-
Still strapped for cash
Nature Biotechnology (2009)
-
Erratum: Biotech sector ponders potential 'bloodbath'
Nature Biotechnology (2009)